We hope that you are all well, taking reasonable precautions, and that your health and businesses remain strong. Your McCarter team is working as usual (albeit remotely) and remains steadfast in our commitment to helping our clients achieve their goals and meet today’s unique challenges. We are working collaboratively across our practices to provide you with the most timely information concerning the Coronavirus pandemic on our Coronavirus Task Force Resource Center. We also will reach out to our contacts proactively as information important to their business operations becomes available.
You may be interested in New York City’s newly adopted employee retention grant program available to New York City-based small businesses with no more than four employees suffering a 25% or more decrease in revenue as a result of COVID-19. If you are a startup/emerging growth company or a venture capital firm with portfolio companies that might qualify for this program, please reach out to us with any questions.
Many of our publicly held clients are in the midst of proxy and annual meeting season. In light of the COVID-19 problems, as well as state and local mandates prohibiting large group meetings, the staff of the Division of Corporate Financing and the Division of Investment Management of the U.S. Securities and Exchange Commission published guidance on March 13, 2020, that relates to public companies conducting their annual meetings virtually instead of in-person. Please click here for more information.
For New Jersey businesses that are being financially and/or operationally impacted by the coronavirus outbreak, the New Jersey Economic Development Authority (NJEDA) has set up an information page to address concerns. In addition to a portfolio of loan, financing, and technical assistance programs available to support the small and medium-sized businesses affected, the NJEDA has programs, initiatives, and incentives for all technology and life sciences enterprises, entrepreneurs, and investors. The materials are provided for your reference on this page.
McCarter has a thriving life sciences practice that brings substantial experience in the pharmaceutical, medical device, biotechnology, and healthcare fields to established organizations and startup life sciences ventures. We are proud to collaborate with Mount Sinai Innovation Partners on its pitch challenge programming, where our attorneys will act as mentors and hear teams present their technology-based ideas and innovative products.
Lawyers in McCarter’s Venture Capital & Emerging Growth Companies Practice group empower clients throughout the development cycle—from ideation to creation, capitalization, implementation, commercialization and monetization.
Media Mentions
2.3.2020 Amy Haberman authored “New Form I-9 Required as of January 31, 2020”—Immigration Alert
2.11.2020 Zack Hadzismajlovic and Ronald M. Leibman discussed “CFIUS: Final Regulations Governing Review of Foreign Investment in US Businesses and Real Estate”—McCarter On Demand Podcast
Additional Resources
